Q-omics provides the consensus-scored NLRP4 profile across patient tissues and cancer cell-line models. NLRP4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NLRP4 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, NLRP4 RNA expression shows 9,885 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where NLRP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP4 survival associations across molecular data types. NLRP4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP4 RNA expression–survival associations across cancer types. High NLRP4 expression shows unfavorable associations in ACC, OV and THCA, but favorable associations in UCS, CHOL and THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NLRP4 RNA expression.
This table summarizes NLRP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NLRP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP4 shows lower tumor expression in THCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher NLRP4 RNA expression in tumor versus normal tissue (log2 FC = +0.134, t-test p = .007).
This table shows molecular features associated with NLRP4 in patient tissues and cancer cell lines. In patient samples, NLRP4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
